CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today results of a prospective analysis of its Phase 2b clinical trial data (BP-21) suggesting that the addition of quantitative SPECT imaging with Zemiva (Iodofiltic acid I 123) to clinical information obtained in the emergency department setting has significant clinical value in rapidly identifying chest pain patients at high risk for acute coronary syndrome (ACS). The Company reported this analysis in a poster at the 2008 Scientific Sessions of the American Heart Association (AHA). The design of this analysis parallels the Company’s ongoing planned pivotal Phase 2 registration trial for Zemiva (BP-23). Top-line results from the BP-23 trial, which will include Zemiva’s performance in the detection of cardiac ischemia as well as ACS, the most severe form of cardiac ischemia, are expected by year-end.
